======= ST3GAL5 ======= == Gene Information == * **Official Symbol**: ST3GAL5 * **Official Name**: ST3 beta-galactoside alpha-2,3-sialyltransferase 5 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=8869|8869]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q9UNP4|Q9UNP4]] * **Interactions**: [[https://thebiogrid.org/search.php?search=ST3GAL5&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20ST3GAL5|Open PubMed]] * **OMIM**: [[https://omim.org/entry/604402|Open OMIM]] == Function Summary == * **Entrez Summary**: Ganglioside GM3 is known to participate in the induction of cell differentiation, modulation of cell proliferation, maintenance of fibroblast morphology, signal transduction, and integrin-mediated cell adhesion. The protein encoded by this gene is a type II membrane protein which catalyzes the formation of GM3 using lactosylceramide as the substrate. The encoded protein is a member of glycosyltransferase family 29 and may be localized to the Golgi apparatus. Mutation in this gene has been associated with Amish infantile epilepsy syndrome. Transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]. * **UniProt Summary**: Catalyzes the formation of ganglioside GM3 (alpha-N- acetylneuraminyl-2,3-beta-D-galactosyl-1, 4-beta-D- glucosylceramide). {ECO:0000269|PubMed:16934889}. |Glyco transf 29| |lactosylceramide alpha-2,3-sialyltransferase activity| |neolactotetraosylceramide alpha-2,3-sialyltransferase activity| |ganglioside biosynthetic process| |sialyltransferase activity| |ganglioside metabolic process| |sialylation| |glycosphingolipid biosynthetic process| |ceramide biosynthetic process| |glycosphingolipid metabolic process| |glycolipid biosynthetic process| |ceramide metabolic process| |sphingolipid biosynthetic process| |glycolipid metabolic process| |liposaccharide metabolic process| |membrane lipid biosynthetic process| |sphingolipid metabolic process| |membrane lipid metabolic process| |protein glycosylation| |macromolecule glycosylation| |glycosylation| |glycoprotein biosynthetic process| |glycoprotein metabolic process| |carbohydrate metabolic process| |amide biosynthetic process| |lipid biosynthetic process| |Golgi membrane| |carbohydrate derivative biosynthetic process| |cellular amide metabolic process| |cellular lipid metabolic process| |carbohydrate derivative metabolic process| |lipid metabolic process| |integral component of plasma membrane| |organonitrogen compound biosynthetic process| |cellular nitrogen compound biosynthetic process| |cellular macromolecule biosynthetic process| |macromolecule biosynthetic process| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp506|Momordin-Ic 10μM R08 exp506]]|-1.84| |[[:results:exp306|Rapamycin 2μM R07 exp306]]|-1.77| |[[:results:exp335|Aminopterin 0.005μM R07 exp335]]|-1.7| |[[:results:exp10|CCCP 0.1μM R00 exp10]]|1.77| |[[:results:exp32|Rifampicin 10μM R00 exp32]]|1.85| No correlation found to any other genes in chemogenomics. Global Fraction of Cell Lines Where Essential: 0/739 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|0/28| |bone|0/26| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/16| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/16| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|0/15| |prostate|0/1| |skin|0/24| |soft tissue|0/9| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 8558 * **Expression level (log2 read counts)**: 3.39 {{:chemogenomics:nalm6 dist.png?nolink |}}